These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 25007316)

  • 21. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
    Park S; Chapuis N; Saint Marcoux F; Recher C; Prebet T; Chevallier P; Cahn JY; Leguay T; Bories P; Witz F; Lamy T; Mayeux P; Lacombe C; Demur C; Tamburini J; Merlat A; Delepine R; Vey N; Dreyfus F; Béné MC; Ifrah N; Bouscary D;
    Leukemia; 2013 Jul; 27(7):1479-86. PubMed ID: 23321953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neutrophilic eccrine hidradenitis secondary to thioguanine in a neutropenic patient].
    Rodríguez Bujaldon A; Vázquez C; Jiménez-Puya R; Galán M; Vélez A; Moreno JC; Rojas R; Arqueros V
    Actas Dermosifiliogr; 2005 Nov; 96(9):583-5. PubMed ID: 16476301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical image. A rare complication of cytarabine therapy.
    Geethakumari PR; Nair SG
    N Z Med J; 2013 Aug; 126(1380):79-80. PubMed ID: 24126753
    [No Abstract]   [Full Text] [Related]  

  • 24. Daunorubicin-induced hyperpigmentation.
    Pol RR; Wright A; Hill A
    Br J Haematol; 2010 Dec; 151(5):414. PubMed ID: 21029070
    [No Abstract]   [Full Text] [Related]  

  • 25. [Neurotoxicity of antineoplastic antimetabolites and antineoplastic antibiotics].
    Morimatsu M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):571-5. PubMed ID: 10434724
    [No Abstract]   [Full Text] [Related]  

  • 26. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
    Sitar DS; Aoki FY; Bow EJ
    J Clin Pharmacol; 2008 Aug; 48(8):995-8. PubMed ID: 18495946
    [No Abstract]   [Full Text] [Related]  

  • 27. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
    Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
    Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
    [No Abstract]   [Full Text] [Related]  

  • 29. Chest and back pain associated with a six-hour infusion of liposomal daunorubicin.
    Hui YF; Cortes JE
    Ann Pharmacother; 2000 Jun; 34(6):810-1. PubMed ID: 10860143
    [No Abstract]   [Full Text] [Related]  

  • 30. Gastroparesis associated with high-dose cytosine arabinoside.
    To T; Coghlan D
    Intern Med J; 2008 Feb; 38(2):143-4. PubMed ID: 18290834
    [No Abstract]   [Full Text] [Related]  

  • 31. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract]   [Full Text] [Related]  

  • 32. Two cases of cytarabine syndrome successfully resolved by desensitization.
    Lim KH; Kim JY; Kang MG; Park HK; Kang HR
    J Investig Allergol Clin Immunol; 2015; 25(1):80-2. PubMed ID: 25898709
    [No Abstract]   [Full Text] [Related]  

  • 33. Images in clinical medicine. Palmar-plantar rash with cytarabine therapy.
    Rosenbeck L; Kiel PJ
    N Engl J Med; 2011 Jan; 364(3):e5. PubMed ID: 21247311
    [No Abstract]   [Full Text] [Related]  

  • 34. [Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
    Brodsky AL; Melero MJ; Minissale CJ; Sánchez Avalos JC
    Medicina (B Aires); 1996; 56(4):327-32. PubMed ID: 9138335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytarabine-induced corneal toxicity.
    Lochhead J; Salmon JF; Bron AJ
    Eye (Lond); 2003 Jul; 17(5):677-8. PubMed ID: 12855993
    [No Abstract]   [Full Text] [Related]  

  • 36. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
    Taverna C; Jacky E; Sauter C
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347
    [No Abstract]   [Full Text] [Related]  

  • 37. Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution.
    Romani C; Pettinau M; Murru R; Angelucci E
    Eur J Cancer Care (Engl); 2009 May; 18(3):320-1. PubMed ID: 19432920
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
    Nobile MT; Pronzato P; Campora E; Ardizzoni A; Grimaldi A; Lionetto R; Repetto L; Rosso R
    G Ital Chemioter; 1985; 32(1):29-30. PubMed ID: 3913619
    [No Abstract]   [Full Text] [Related]  

  • 39. [Acute heart failure after a moderate dose of rubidomycin].
    Baledent M; Messerschmitt J; Bens JL; Quiret JC; Faille N
    Sem Hop; 1972 Feb; 48(7):507-10. PubMed ID: 4338408
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute myeloblastic leukemia in adults.
    Kasthuri AS; Jaiprakash MP; Anand KP; Kumar R
    J Assoc Physicians India; 1995 Feb; 43(2):108-10. PubMed ID: 9282674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.